Lorenzo Leggio
Clinical Director · Clinical Center at the National Institutes of Health
Credentials: · · ·
History
Research
The Lancet · 2007 · 525 citations
Advances in the science and treatment of alcohol use disorder
Review · Science Advances · 2019 · Last of 3 authors · Corresponding · 431 citations
Review · European Journal of Internal Medicine · 2008 · 225 citations
- RS
44 papers
- LF
16 papers
- NM
11 papers
9 papers · 4 as a resident
8 papers
8 papers
7 papers
- AJ
6 papers
Grants
- 2013–2020
A Novel Compound for Alcoholism Treatment: A Translational Strategy
National Center for Advancing Translational Sciences · UH3
PI · $1.1M · University of Rhode Island
- 2013–2014
A Novel Compound for Alcoholism Treatment: A Translational Strategy
National Center for Advancing Translational Sciences · UH2
PI · $550.5K · University of Rhode Island
- 2010–2012
Effects of Ghrelin on Alcohol Cue Reactivity and Craving
National Institute on Alcohol Abuse and Alcoholism · R21
Contact PI · $202.5K · Brown University
- 2010–2012
Effect of Baclofen on Alcohol Cue-Elicited Urges to Drink and Smoke
National Institute on Alcohol Abuse and Alcoholism · R03
Contact PI · $40.5K · Brown University
Clinical trials
- 2026–2028
Environment and Alcohol: A Pilot Study
Principal investigator · Recruiting · Phase 1
National Institute on Drug Abuse (NIDA)
- 2024–2047
Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP
Principal investigator · Recruiting
National Institute on Drug Abuse (NIDA)
- 2023–2027
Semaglutide Therapy for Alcohol Reduction (STAR)
Principal investigator · Active not recruiting · Phase 2
National Institute on Drug Abuse (NIDA)
- 2023–2027
Spironolactone in Alcohol Use Disorder (SAUD)
Principal investigator · Recruiting · Phase 1
National Institute on Drug Abuse (NIDA)